Intensity Therapeutics Azioni (NASDAQ: INTS)

Ultime notizie per Intensity Therapeutics (NASDAQ:INTS) Azioni

Intensity Therapeutics

Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with major unmet medical need.

Intensity Therapeutics, Inc. - Common Stock

Intensity Therapeutics Inc

Biotech

Earnings

News

Guidance

Health Care

General

NTLA

Intellia Ended The Third Quarter Of 2024 With Approximately $944.7M In Cash, Cash Equivalents And Marketable Securities, The Cash Position Is Expected To Fund Operations Into Late 2026

Altimmune Announces Completion Of End-of-Phase 2 Meeting With FDA For Pemvidutide In Obesity Treatment; Company And Agency Aligned On Key Efficacy And Safety Measures To Be Studied In Phase 3 Program

<p>Intellia Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTLA#NASDAQ">NTLA</a>) reported quarterly losses of $(1.34) per share which beat the analyst consensus estimate of $(1.40) by 4.29 percent.</p>


Intellia Therapeutics Q3 2024 GAAP EPS $(1.34) Beats $(1.40) Estimate

<p>UBS  analyst Steven Fisher   initiates coverage on Vulcan Materials (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMC#NYSE">VMC</a>) with a Buy rating and announces Price Target of $349.</p>


Price Target

Initiation

Analyst Ratings

UBS Initiates Coverage On Vulcan Materials with Buy Rating, Announces Price Target of $349

<p>WhiteHorse Finance (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WHF#NASDAQ">WHF</a>) reported quarterly earnings of $0.39 per share which missed the analyst consensus estimate of $0.41 by 3.9 percent. This is a 15.27 percent decrease over earnings of $0.47 per share from the same period last year.  The company reported quarterly sales of $22.851 million which missed the analyst consensus estimate of $23.203 million by 1.52 percent.  This is a 2.69 percent decrease over sales of $23.482 million the same period last year.</p>


Earnings Misses

WhiteHorse Finance Q3 2024 Adj. EPS $0.39 Misses $0.41 Estimate, Sales $22.851M Miss $23.203M Estimate

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates ACADIA Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACAD#NASDAQ">ACAD</a>) with a Buy and maintains $27 price target.</p>


Reiteration

ACAD

HC Wainwright & Co. Reiterates Buy on ACADIA Pharmaceuticals, Maintains $27 Price Target

HOUS

Anywhere Real Estate Q3 2024 Adj. EPS $0.06 May Not Compare To $0.29 Estimate, Sales $1.535B Miss $1.624B Estimate

<p><strong>Fourth Quarter and 2024 Outlook</strong></p>
<p>The Company is reaffirming its fiscal year 2024 outlook of 4.5% to 5.5% revenue growth, based on year-to-date performance and current business trends. For the fourth quarter, the Company anticipates continued strong high single digit year-over-year growth in OEM &amp; National revenue, as well as modest growth in Dealer revenue.</p>
<p>Adjusted EBITDA margin outlook for fiscal 2024 remains 28.0% to 30.0%, reflecting disciplined cost management to continue delivering strong operating leverage for the remainder of the year.</p>


CARS

Cars.com Reaffirms FY24 Revenue Outlook 4.5%-5.5% Growth

MTSI

MACOM Sees Q1 Adj. EPS $0.75-$0.81

<p>The earnings results for <strong>Clear Channel Outdoor</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCO#NYSE">CCO</a>) for Q3 were made public on Thursday, October 31, 2024 at 06:00 AM.</p>
<p>Here's a comprehensive overview of the announcement.</p>
<h3>Earnings</h3>
<p>Clear Channel Outdoor missed estimated earnings by 0.0%, reporting an EPS of $-0.06 versus an estimate of $-0.06.</p>
<p>Revenue was up $32.20 million from the same period last year.</p>
<h3>Performance in Previous Earnings</h3>
<p>During the previous quarter, the company beat on EPS by $0.01, leading to a 3.0% drop share price change the next day.</p>
<p>Here's a look at Clear Channel Outdoor's past performance:</p>
<p>
<table>
<thead>
<tr>
<th><strong>Quarter</strong></th>
<th><strong>Q3 2024</strong></th>
<th><strong>Q2 2024</strong></th>
<th><strong>Q1 2024</strong></th>
<th><strong>Q4 2023</strong></th>
<th><strong>Q3 2023</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>EPS Estimate</strong></td>
<td>-0.06</td>
<td>-0.05</td>
<td>-0.17</td>
<td>0.04</td>
<td>-0.08</td>
</tr>
<tr>
<td><strong>EPS Actual</strong></td>
<td>-0.06</td>
<td>-0.04</td>
<td>-0.17</td>
<td>0.05</td>
<td>-0.11</td>
</tr>
<tr>
<td><strong>Revenue Estimate</strong></td>
<td>557.41M</td>
<td>562.37M</td>
<td>478.55M</td>
<td>610.14M</td>
<td>594.92M</td>
</tr>
<tr>
<td><strong>Revenue Actual</strong></td>
<td>558.99M</td>
<td>558.54M</td>
<td>481.75M</td>
<td>632.11M</td>
<td>526.79M</td>
</tr>
</tbody>
</table>
</p>
<h3>Latest Earnings Reports from Competitors</h3>
<p>With Clear Channel Outdoor's earnings data in hand, it's essential to compare its metrics to those of similar companies, including PubMatic, TechTarget, and National CineMedia.</p>
<ul>
<li>The latest earnings announcement from PubMatic on August 08, 2024 exceeded expectations, with an actual EPS of $0.17 compared to the market's estimate of $-0.02, resulting in a 950.0% increase.</li>
<li>The latest earnings announcement from TechTarget on August 08, 2024 exceeded expectations, with an actual EPS of $0.42 compared to the market's estimate of $0.4, resulting in a 5.0% increase.</li>
<li>The latest earnings report from National CineMedia on November 05, 2024 showed a downturn in performance, with results falling short of expectations. Despite the market's EPS estimate of $-0.03, National CineMedia reported an EPS of $-0.04, marking a -33.33% decrease.</li>
</ul>
<h3>Quarterly Analysis: Competitors' Earnings and Stock Performance</h3>
<p>The provided analysis offers insights into the market's response to the latest earnings releases of key competitors. It highlights the expected and announced earnings per share (EPS) for each company, along with their corresponding stock prices at the close of the announcement day and the open of the following trading day.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Date</strong></th>
<th style="text-align: right;"><strong>EPS Expected</strong></th>
<th style="text-align: right;"><strong>EPS Announced</strong></th>
<th><strong>EPS Change Percent</strong></th>
<th><strong>Stock Price At Close</strong></th>
<th><strong>Stock Price at Next Day Open</strong></th>
<th><strong>Price Change Percent</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>October 31, 2024</td>
<td style="text-align: right;">-0.06</td>
<td style="text-align: right;">-0.06</td>
<td>0.0%</td>
<td>$1.47</td>
<td>$1.48</td>
<td>0.68%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>August 08, 2024</td>
<td style="text-align: right;">-0.02</td>
<td style="text-align: right;">0.17</td>
<td>950.0%</td>
<td>$19.6</td>
<td>$13.82</td>
<td>-29.49%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>August 08, 2024</td>
<td style="text-align: right;">0.40</td>
<td style="text-align: right;">0.42</td>
<td>5.0%</td>
<td>$29.02</td>
<td>$28.38</td>
<td>-2.21%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>November 05, 2024</td>
<td style="text-align: right;">-0.03</td>
<td style="text-align: right;">-0.04</td>
<td>-33.33%</td>
<td>$7.3</td>
<td>$7.35</td>
<td>0.68%</td>
</tr>
</tbody>
</table>
</p>
<h3>Delving into Peer Revenue Comparison: Estimated vs. Announced</h3>
<p>Below is a comparison of estimated and announced revenue figures for Clear Channel Outdoor's peers. This comparison gives insights into the revenue performance of these companies, providing valuable context for understanding their financial standing within the industry.</p>
<p>
<table>
<thead>
<tr>
<th><strong>Company Name</strong></th>
<th><strong>Estimated Revenue</strong></th>
<th><strong>Announced Revenue</strong></th>
<th><strong>Revenue Surprise Percentage</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>Clear Channel Outdoor</td>
<td>557.41M</td>
<td>558.99M</td>
<td>0.28%</td>
</tr>
<tr>
<td>PubMatic</td>
<td>70.12M</td>
<td>67.27M</td>
<td>-4.07%</td>
</tr>
<tr>
<td>TechTarget</td>
<td>58.08M</td>
<td>58.91M</td>
<td>1.44%</td>
</tr>
<tr>
<td>National CineMedia</td>
<td>58.02M</td>
<td>62.40M</td>
<td>7.55%</td>
</tr>
</tbody>
</table>
</p>
<p>To track all earnings releases for Clear Channel Outdoor <a href="https://www.benzinga.com/quote/CCO/earnings">visit their earnings calendar here.</a> </p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Insights into Clear Channel Outdoor Q3 Earnings

<p>MACOM Technology Solns (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSI#NASDAQ">MTSI</a>) reported quarterly earnings of $0.73 per share which met the analyst consensus estimate.  The company reported quarterly sales of $200.710 million which beat the analyst consensus estimate of $200.406 million by 0.15 percent.  This is a 33.47 percent increase over sales of $150.375 million the same period last year.</p>


Earnings Beats

MACOM Technology Solns Q4 2024 Adj. EPS $0.73, Inline, Sales $200.710M Beat $200.406M Estimate

Turning Point Brands Raised Previous Full-year 2024 Adjusted EBITDA Guidance From $98M-$102M To $101M-$103M, Excluding CDS

THRY

Thryv Holdings See FY24 Adj. EBITDA $33.5M-$34.5M

Thryv Holdings Sees Q4 Adj. EBITDA $9.5M-$10.5M

<p>Seaport Global  analyst Aaron Kessler   downgrades Duolingo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DUOL#NASDAQ">DUOL</a>) from Buy to Neutral.</p>


Downgrades

DUOL

Seaport Global Downgrades Duolingo to Neutral

<p>HC Wainwright &amp; Co.  analyst Andrew Fein   reiterates Denali Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DNLI#NASDAQ">DNLI</a>) with a Buy and maintains $90 price target.</p>


DNLI

HC Wainwright & Co. Reiterates Buy on Denali Therapeutics, Maintains $90 Price Target

<p>Anywhere Real Estate (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HOUS#NYSE">HOUS</a>) reported quarterly sales of $1.53 billion which missed the analyst consensus estimate of $1.62 billion by 5.46 percent.  This is a 3.09 percent decrease over sales of $1.58 billion the same period last year.</p>


Anywhere Real Estate Q3 Sales $1.53B Miss $1.62B Estimate

Stock Split

TRNR

Interactive Strength Announces 1-For-100 Reverse Split, Effective November 11

<p><strong>2024 Fourth Quarter Financial Outlook</strong></p>
<p>Management provided an outlook for the fourth quarter, the period ending December 31, 2024. Based on current estimates, management expects:</p>
<ul>
<li>$181 million to $191 million in revenue</li>
<li>$1.51 to $1.70 in diluted GAAP EPS</li>
<li>$1.72 to $1.91 in diluted non-GAAP EPS</li>
</ul>


NVMI

Nova Expects Q4 Revenue Of $181M-$191M Vs $171.84M Est, Adj EPS Of $1.72-$1.91 Vs $1.68 Est

<p>Thryv Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/THRY#NASDAQ">THRY</a>) reported quarterly losses of $(2.65) per share which missed the analyst consensus estimate of $(0.95) by 178.95 percent.  The company reported quarterly sales of $179.852 million which beat the analyst consensus estimate of $179.230 million by 0.35 percent.  This is a 2.16 percent decrease over sales of $183.822 million the same period last year.</p>


Thryv Holdings Q3 2024 GAAP EPS $(2.65) Misses $(0.95) Estimate, Sales $179.852M Beat $179.230M Estimate

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intensity Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ints-stock-quote/"><strong>INTS</strong></a></span>) just reported results for the first quarter of 2024.</p><ul><li>Intensity Therapeutics reported earnings per share of -34 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	<p>The post <a href="https://investorplace.com/earning-results/2024/05/ints-stock-earnings-intensity-therapeutics-for-q1-of-2024/">INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

INTS Stock Earnings: Intensity Therapeutics Reported Results for Q1 2024

Intensity Therapeutics GAAP EPS of -$0.34

Intensity Therapeutics: A Bargain For A Late-Stage Company With A Remarkable Oncology Drug

Intensity Therapeutics, Inc. (INTS) has shared an announcement. Intensity Therapeutics, Inc. has expanded its Board of Directors by appointing Thom...

Intensity Therapeutics Expands Board, Welcomes New Audit Director

Intensity Therapeutics files to sell common stock by selling stockholders

Intensity Therapeutics, Inc. (INTS) has provided an announcement. Intensity Therapeutics, Inc. successfully conducted its Annual Meeting via live w...

Intensity Therapeutics Shareholders Engage and Elect at Annual Meeting

Intensity Therapeutics GAAP EPS of -$0.36

<p><a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a></p>
<p><strong>Intensity Therapeutics</strong> (NASDAQ:<span><a href="https://investorplace.com/stock-quotes/ints-stock-quote/"><strong>INTS</strong></a></span>) just reported results for the second quarter of 2024.</p><ul><li>Intensity Therapeutics reported earnings per share of -36 cents. This was below the analyst estimate for EPS of -32 cents.</li><li>The company did not report any revenue for the quarter.</li></ul><div><p>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</p></div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget AI... THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><p>The post <a href="https://investorplace.com/earning-results/2024/08/ints-stock-earnings-intensity-therapeutics-for-q2-of-2024/">INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.</p>

INTS Stock Earnings: Intensity Therapeutics Misses EPS for Q2 2024

Intensity Therapeutics, Inc. (INTS) has received a new Buy rating, initiated by H.C. Wainwright analyst, Swayampakula Ramakanth. Swayampakula Ramak...

Innovative Cancer Treatment Approach Positions Intensity Therapeutics as a Compelling Investment Opportunity

Intensity Therapeutics (INTS) and The Swiss Group for Clinical Cancer Research SAKK, a decentralized academic research institute that has been cond...

Intensity Therapeutics announces first dosing in Phase 2 trial of INT230-6

INTS

Press Releases

Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update

Financing

Portage Biotech Completes Monetization of Intensity Therapeutics (INTS) shares

Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024

Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity's Lead Drug Candidate

Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors

Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma

Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Intensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)

Comments

Intensity Therapeutics

Notizie

Ultime notizie per Intensity Therapeutics (NASDAQ:INTS) Azioni

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO